Paxlovid didn’t shorten Covid symptoms in vaccinated adults, full trial results confirm

“If it’s Covid, Paxlovid.”

That’s how Pfiz­er mar­kets its Covid-19 an­tivi­ral, even as the full re­sults of a study pub­lished in the New Eng­land Jour­nal of Med­i­cine this week adds fur­ther proof that the pill may not be as ef­fec­tive in vac­ci­nat­ed adults and those at low risk for se­vere symp­toms.

The full study re­sults were pub­lished in NE­JM on Wednes­day, though Pfiz­er re­leased the ini­tial re­sults back in 2022. Paxlovid was grant­ed full ap­proval last May to treat mild-to-mod­er­ate Covid-19 in adults at high risk for de­vel­op­ing se­vere Covid-19, af­ter it was first made avail­able un­der an emer­gency use au­tho­riza­tion in 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.